Brentuximab Vedotin in CD30+ Lymphomas

Monoclonal antibodies (mAb) have become an effective treatment strategy for hematologic malignancies. CD30 is a rational target for therapy due to its limited expression on normal tissues and the strong and uniform expression on malignant cells in classical Hodgkin’s lymphoma (cHL) and anaplastic la...

Descripción completa

Detalles Bibliográficos
Autores principales: Perini, Guilherme Fleury, Pro, Barbara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873074/
https://www.ncbi.nlm.nih.gov/pubmed/24392301
http://dx.doi.org/10.1007/s13554-013-0008-7
_version_ 1782297055420481536
author Perini, Guilherme Fleury
Pro, Barbara
author_facet Perini, Guilherme Fleury
Pro, Barbara
author_sort Perini, Guilherme Fleury
collection PubMed
description Monoclonal antibodies (mAb) have become an effective treatment strategy for hematologic malignancies. CD30 is a rational target for therapy due to its limited expression on normal tissues and the strong and uniform expression on malignant cells in classical Hodgkin’s lymphoma (cHL) and anaplastic large-cell lymphoma (ALCL). Brentuximab vedotin, an anti-CD30 antibody-drug conjugate, utilizes the targeting properties of mAb to deliver a cytotoxic agent inside the malignant cell. Brentuximab vedotin has significant clinical activity in patients with relapsed or refractory cHL and relapsed or refractory ALCL, and has the potential to represent a significant advance in modern oncology.
format Online
Article
Text
id pubmed-3873074
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-38730742014-01-02 Brentuximab Vedotin in CD30+ Lymphomas Perini, Guilherme Fleury Pro, Barbara Biol Ther Review Monoclonal antibodies (mAb) have become an effective treatment strategy for hematologic malignancies. CD30 is a rational target for therapy due to its limited expression on normal tissues and the strong and uniform expression on malignant cells in classical Hodgkin’s lymphoma (cHL) and anaplastic large-cell lymphoma (ALCL). Brentuximab vedotin, an anti-CD30 antibody-drug conjugate, utilizes the targeting properties of mAb to deliver a cytotoxic agent inside the malignant cell. Brentuximab vedotin has significant clinical activity in patients with relapsed or refractory cHL and relapsed or refractory ALCL, and has the potential to represent a significant advance in modern oncology. Springer Healthcare 2013-03-01 /pmc/articles/PMC3873074/ /pubmed/24392301 http://dx.doi.org/10.1007/s13554-013-0008-7 Text en © The Author(s) 2013 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Review
Perini, Guilherme Fleury
Pro, Barbara
Brentuximab Vedotin in CD30+ Lymphomas
title Brentuximab Vedotin in CD30+ Lymphomas
title_full Brentuximab Vedotin in CD30+ Lymphomas
title_fullStr Brentuximab Vedotin in CD30+ Lymphomas
title_full_unstemmed Brentuximab Vedotin in CD30+ Lymphomas
title_short Brentuximab Vedotin in CD30+ Lymphomas
title_sort brentuximab vedotin in cd30+ lymphomas
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873074/
https://www.ncbi.nlm.nih.gov/pubmed/24392301
http://dx.doi.org/10.1007/s13554-013-0008-7
work_keys_str_mv AT periniguilhermefleury brentuximabvedotinincd30lymphomas
AT probarbara brentuximabvedotinincd30lymphomas

Ejemplares similares